Juno Therapeutics Inc., a biopharmaceutical company developing cellular immunotherapies for the treatment of cancer, released additional data from the TRANSCEND study of JCAR017 (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in a presentation at the 59th American Society of Hematology Annual Meeting and Exposition.
The phase III EMBRACA trial in patients with germline BRCA1/2-positive locally advanced and/or metastatic breast cancer demonstrated superior progression-free survival in patients treated with talazoparib, compared to patients who received physician's choice standard of care chemotherapy.
DONALD BROWN donated $30 million to Indiana University School of Medicine to establish the Brown Center for Immunotherapy. The Brown Center for Immunotherapy will initially focus on multiple myeloma and triple negative breast cancer, two diseases for which the School of Medicine and its clinical partner Indiana University Health have a strong foundation of talent,... […]
PROTON PARTNERS INTERNATIONAL LTD will invest £30 million in a new cancer center which will be located at the Thames Valley Science Park, UK, offering proton beam therapy among other conventional cancer therapies. Located in Reading, Berkshire, the center will be the third to be built in the UK by Proton Partners and will help... […]
ELLIS NEUFELD was appointed clinical director, physician-in-chief and executive vice president of St. Jude Children’s Research Hospital. Beginning in March 2017, Neufeld will oversee the organization’s academic clinical departments and all clinical operations. The appointment comes as St. Jude looks to increase the number of cancer patients treated at its campus and on protocols around... […]
BILL ANDERSON was named CEO of Genentech, which is a member of the Roche Group, effective Jan. 1, 2017. He takes over from Ian T. Clark who retires at the end of 2016 after 14 years of service. Anderson, who is also the head of North American commercial operations, has served in a number of... […]
FRANCIS COLLINS, the NIH director, received the 2017 Public Service Award from the Federation of American Societies for Experimental Biology “for his outstanding accomplishments in the communication of science.” “Francis Collins is a model of scientific citizenship. His passion for public education has been an inspiration, and his leadership has motivated thousands of scientists to... […]
JAMES AND MIRIAM MULVA and the Mulva Family Foundation donated $50 million to advance neuroscience at UT Austin and another $25 million for cancer research at MD Anderson Cancer Center. The total $75 million gift to the two UT institutions will advance health care in Texas and globally. The $25 million grant supports MD Anderson’s... […]
THE ASSOCIATION OF COMMUNITY CANCER CENTERS, partnered with the Avon Breast Cancer Crusade, the Cancer Support Community, and the Metastatic Breast Cancer Alliance, announced the launch of a website designed to provide educational information supporting patients diagnosed with metastatic breast cancer. The site pulls together vetted tools and resources to support patient engagement and education,... […]
ABILITY PHARMACEUTICALS of Barcelona, Spain, received orphan-drug designation from FDA for ABTL0812, for the treatment of pancreatic cancer. This regulatory milestone comes after the ODD in the pediatric cancer neuroblastoma granted by EMA and FDA in 2015. In preclinical studies, ABTL0812 have shown efficacy in pancreatic cancer as single agent and synergistic effect (by 8... […]
